Connect with us

Regulations

GOP Congressman Presents CBD Products During Hearing

Published

on

GOP Congressman bats for CBD

A congressman from the Grand Old Party brought two CBD-containing products he uses personally last Tuesday during a hearing to point out the distinctions between marijuana and hemp.

The House Oversight Committee held a meeting on the incidences of vaping-related issues when Kentucky Rep. James Comer spent his time discussing CBD. He believes that there is still a lot of confusion and misinformation regarding the nature of CBD and THC.

He stated that many people are now using CBD or cannabidiol, including Congress members and the million other Americans like he also does.

Showcasing the CBD Products

Comer showed the products during his time on the floor and likened the difference between hemp and marijuana by parallelizing it with broccoli and cauliflower. He stated that both are from the same family with many similarities, but ultimately different from each other.

He also said that most Americans are taking CBD extracted from the hemp variety and not marijuana, which gives them better and more positive effects than the latter.

Comer discussed his personal experience with CBD preparations, to which he said that the manufacturers and companies he visited produce good, legitimate CBD products. He was formerly a state agriculture commissioner before he came to Congress.

However, he acknowledged the need for more regulations to guide the industry. He pointed out the lack of regulations on CBD oil from the Food and Drug Administration (FDA). He goes on to say that credible, legitimate companies are pushing for more regulations.

Comer also mentioned the bipartisan letter he penned with 24 other lawmakers, which was addressed to the FDA regarding the agency’s signal so that CBD can be marketed legally.

He also stated that he is a conservative, pro-business person, which normally pits him against regulations. However, it believes that the CBD industry needs to be regulated.

A word from other Congressmen

Glenn Grothman, a Wisconsin representative, called on the Centers for Disease Control and Prevention deputy director to illuminate the matter regarding the vaping injuries issue, asking whether legal shops that sell cannabis across states contribute to the rising number of cases.

He stated that although THC is still illegal in most states, some states are catching up on the rise of marijuana legalization. Grothman relayed his doubts about whether vape cartridges have also been legalized in states that deem marijuana lawful.

The deputy director responded by saying that she did not know, which prompted Grothman to convey his concern regarding the legalization of marijuana in Illinois, which sounds like trouble for him.

Virginia Representative Gerry Connolly from the Democratic party likened the lack of regulations for vape and vaping products to the federal government’s dismissal of marijuana for many years.

Connolly said that the federal government has failed to classify and categorize marijuana, which makes it seem to him that they have not done a good job regarding such an issue. He noted how it had limited the number of sponsored researches and how proponents are chosen, which is commonly by bias. It has resulted in the government’s loss of control regarding marijuana.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Regulations

Is Charlotte’s Web in Trouble After Recent CBD Warning by FDA?

Published

on

The cannabidiol industry is set towards an impressive expansion. According to a research firm forecast, CBD sales could reach $20B by 2024, almost tenfold from 2018’s sales of $1.8B. It could be attributed to upward trends in the industry, and as well as the great reception to CBD being a safe option compared to marijuana due to its low tetrahydrocannabinol (THC) content. THC is the substance responsible for the high in weed.

However, the Food and Drug Administration (FDA) has issued a warning recently that stated how some CBD-based products could cause serious health problems. This statement might affect one of the leading CBD companies in the US, Charlotte’s Web Holdings.

CBD may not always be healthy

In a consumer update published by the FDA regarding CBD product use, the agency stressed that cannabidiol might be the cause for various health issues such as liver injury, change in mood, and alertness. CBD used with other depressants and alcohol may also cause drowsiness. The FDA added that the said side effects could happen even without the user noticing.

The agency also reiterated that the alleged therapeutic benefits of cannabidiol are mostly unproven, despite several sellers highlighting their products as having several health benefits such as anti-cancer and pain-relieving properties.

The FDA also reminded the public that there is still a lack of data as CBD’s effects on the body in the long term. It is something consumers should ponder about according to the agency.

Is Charlotte’s Web Affected?

Charlotte’s Web is one of the most well-known US-based cannabidiol companies in the country and abroad. It sells a variety of CBD-containing products such as capsules and oil. It claims the biggest US market share in the CBD industry, with its products selling at nearly 10,000 stores nationwide. Its strong retail presence aids in the expansion of the company’s market share. Can the FDA warning affect their numbers?

Most likely not, and Charlotte’s Web can still maintain its top market position. The FDA has sent out warning letters to companies selling CBD products with false promotional claims, but Charlotte’s Web was not included. In a conference call of Charlotte’s Web CEO Deanie Elsner regarding their third-quarter earnings, he specified that the company fully supports the FDA’s stance on unfounded claims and are working with their business partners to maintain the effort.

Elsner also mentioned that while the FDA has little issuance on regulations, Charlotte’s Web is ready to adapt as soon as new directives from the agency are released. He said that the company is currently progressing on its expansion plan, getting its infrastructure and capacity to catch up with its growth.

The company is rooting for the FDA to set a clear regulatory framework, especially for dietary supplements. Charlotte’s Web is positive that its product portfolio and distribution channels will expand as soon as it happens.

The CBD industry looks to persist despite the warnings, and the supply of products will unlikely dwindle. Charlotte’s Web and its growth will remain unaffected. For investors, it might be wise to keep in mind that the CBD legal landscape is still an unfinished course, so evaluating whether a company is worth purchasing shares from is important.

Continue Reading

Regulations

China Cashes in on Cannabis Boom Despite Being Illegal in the Country

Published

on

China Cashes in on Cannabis Boom

Marijuana is a dangerous narcotic in China, and being caught possessing it incurs a grave offense. However, this does not hamper the booming production of cannabis products in the region.

China has been growing hemp for textile and alternative medicine for many centuries and remains to be one of the largest top producers in the world. The giant’s footing in the cannabis industry has given producers an edge in the booming CBD craze. CBD or cannabidiol is a derivative of the cannabis plant that is now infused in virtually anything, from pet products to skincare serums.

The heart of the production

Yunnan, a province in China’s southwestern region, is the first to make industrial cannabis legal. The farm plots in the area are filled with tall hemp fields that span miles. The plant’s flowers and leaves are harvested by hand during the fall, sun-dried, and then turned into export quality CBD oil and powder. Yang Liu, manager of some hemp fields in Qujing, Yunnan, said that the cannabis industry looks to bring great benefit to him and the farmers in the future.

China holds 11% of the $800M worldwide CBD market last year, trailing after the US and Europe.

The industry is still maturing, but manufacturers and other key players in the CBD market are investing in land to increase hemp production. It may have existed for thousands of years, but hemp growing wasn’t adequately regulated until recently, with the government now being intimately involved in the development of the CBD industry.

Henri Sant-Cassia, a CBD advocate representing Cannabis Fund who tours Asia to find new CBD enterprises, exclaimed that China is moving into the cannabidiol industry at the speed of light.

Unbending regulations

Farmers in the US are also upping their hemp cultivation to cope with the rising CBD demand. This cannabis derivative is said to relieve anxiety and pain without causing a high that marijuana gives. The Brightfield Group predicts the CBD market to grow to a $23.7B industry by 2023.

Despite the astounding numbers, China’s stance on marijuana is unlikely to bend. If anyone is found to be harboring tetrahydrocannabinol (THC)-based products, they can be charged with a life sentence or worse, the death penalty. National Narcotics Control Commission deputy director Liu Yuejin said last April that China would strictly supervise industrial cannabis production amid its legalization in many countries.

Ingestible CBD is also regulated in China, which means that almost all hemp harvested and processed in China is sent overseas. It competes with other major hemp producers like Canada and the US for CBD market share.

CBD industry in China

The second province to legalize industrial cannabis farming is Heilongjiang, which is located along the Siberian border in the country’s northeastern area. Neighboring province Jilin is also poised to follow in their footsteps. Government officials are starting to encourage growers to consider hemp production, citing additional income and crop diversification as the benefits.

An influx of new companies entered China’s CBD industry recently, which Hanma Investment Group Co. Co-Founder Tan Xin believes will make it harder for newcomers to gain profit.

Since HMI started their cannabis venture in 2013, a kilo of CBD was valued at $50,000 when sold in the US, as stated by Tan Xin. In 2018, it fell to $6,000 and would most likely drop to $1,000 per kilo in 2020, according to him.

Nevertheless, Tan is positive that they can still cash in, provided that the price does not fall below the $300 mark since processing and labor cost less in China.

Continue Reading

Regulations

Untested CBD-infused Products Could Pose Health Risks as Market Grows Stronger

Published

on

Untested CBD-infused Products Could Pose Health Risks

Cannabidiol products have recently spiked in sales and availability, granted by its popularity as an alternative cure to anxiety and pain. However, medical authorities warn about the potential health hazards of CBD and the many unproven therapeutic claims of the said substance.

Cronos, a Canadian company, recently bought a $300M CBD company, 7-Eleven stores now have CBD-dispensing robots, and HempAmericana Inc. started a live e-commerce portal to foster online CBD sales.

Expert’s opinion

Dr. Dipesh Navsaria, director of the University of Wisconsin’s Doctor of Medicine-Master of Public Health Program, stated that cannabidiol might have numerous benefits, but most of these claims have not been tested for accuracy.

He cited the clinical trials of CBD for intractable seizures as the only benefit proven to be true. Intractable epilepsy is a kind of seizure that does not respond to therapy or any treatment. The CBD-containing drug, Epidiolex, is the only FDA-approved cannabidiol medication given for such cases.

Navsaria reiterated that several claims lack strong evidence for them to count.

Earlier this year, the FDA gave out warning letters to companies that sell new yet unapproved drugs that allegedly have CBD. Three of these firms are located in Florida.

CBD is widely available in stores and online, including big retailers like Walgreens.

Navsaria pointed out the lack of guarantee in terms of a product’s purity, and its active ingredients are what make it hard for medical practitioners to say yes to patients asking whether they can try CBD. It’s is the same dilemma they face for homeopathic remedies and herbal supplements, Navsaria added.

Research on CBD

Forbes revealed cases of people testing positive in urine drug tests from using CBD. This situation poses a risk for people whose jobs stipulate routine drug testing.

Natalie Schmitz, associate professor at the University of Wisconsin School of Pharmacy, studied the labeling accuracy for CBD products in her research. She stated that the literature related to CBD is limited and cannot support the claims of effectiveness.

She added that further research should be done to support all claims, including the benefits of CBD for pain and anxiety so that a conclusive statement can be made.

Some studies show how CBD can cause liver problems. There is also evidence of the substance causing several side effects like irritability, fatigue, and nausea.

Schmitz further stated that there is a need for FDA-approved guidelines for standardization and state-proposed quality measurements to help ensure that CBD products do not pose health hazards for the public.

Navsaria said that people should question products that are claiming to have several benefits without proper evidence. He cited profit motive as a drive for the proliferating CBD market. He believes that sellers are taking advantage of the trend to maximize sales, making it questionable whether these products are actually made to help people.

He further added that claims could easily be made, but there is little to no support over its factual value.

Continue Reading

Trending